Dicot gains significant interest at North America's major sexual medicine congress
Press release: Uppsala, November 24, 2023. During the fall, the pharmaceutical company Dicot received acceptance for an abstract presentation at North America's largest congress in sexual medicine, recently held in San Diego. Dicot's CSO, Charlotta Gauffin, participated alongside Professor François Giuliano, who presented the company's preclinical research findings, and sexual medicine expert Dr. Harin Padma-Nathan.
The annual congress of Sexual Medicine Society of North America is the premier gathering for physicians, researchers, and industry professionals in sexual medicine in North America. Dicot's preclinical results for the potency drug candidate LIB-01 were presented by Professor François Giuliano, who had led the studies and is a recognized urologist with several international awards. Dr. Harin Padma-Nathan also participated in the role of the company's consultant. He is a world-renowned expert in sexual medicine and has served as principal investigator in over 110 clinical trials, including those involving Viagra.
In addition to Professor Giuliano's presentation, Dicot and the LIB-01 research received a lot of attention. This prompted, among other things, an invite from the president of the European Society for Sexual Medicine to submit an abstract for the organization's next congress in Italy. Similarly, Dicot was encouraged to participate in the World Meeting on Sexual Medicine in Rio next year.
"I am proud of all the attention and feel honoured to have participated alongside the prominent experts Professor Giuliano and Dr. Padma-Nathan. It is obvious that they are highly regarded key players within the field. The interest in LIB-01 was significant, and it was evident that an oral treatment with a duration of effect of at least seven days made an impression. We have now put Dicot on the American map," says Charlotta Gauffin, Dicot's Chief Scientific Officer.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market. Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.